JPWO2019213245A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019213245A5
JPWO2019213245A5 JP2020561795A JP2020561795A JPWO2019213245A5 JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP WO2019213245 A5 JPWO2019213245 A5 JP WO2019213245A5
Authority
JP
Japan
Prior art keywords
months
accumulated
composition
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523126A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030184 external-priority patent/WO2019213245A1/en
Publication of JP2021523126A publication Critical patent/JP2021523126A/ja
Publication of JPWO2019213245A5 publication Critical patent/JPWO2019213245A5/ja
Pending legal-status Critical Current

Links

JP2020561795A 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法 Pending JP2021523126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666459P 2018-05-03 2018-05-03
US62/666,459 2018-05-03
PCT/US2019/030184 WO2019213245A1 (en) 2018-05-03 2019-05-01 Methods for reducing accumulated pathologic tau protein

Publications (2)

Publication Number Publication Date
JP2021523126A JP2021523126A (ja) 2021-09-02
JPWO2019213245A5 true JPWO2019213245A5 (enExample) 2022-05-10

Family

ID=66530499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561795A Pending JP2021523126A (ja) 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法

Country Status (4)

Country Link
US (1) US20210137861A1 (enExample)
EP (1) EP3787750A1 (enExample)
JP (1) JP2021523126A (enExample)
WO (1) WO2019213245A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020036656A2 (en) 2018-04-27 2020-02-20 The Regents Of The University Of California Inhibition of lipofuscin aggregation by molecular tweezers
US12076332B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Treatment of lysosomal storage disorders
JP2023514742A (ja) * 2020-02-24 2023-04-07 オブラート，インコーポレーテッド がん及び腫瘍を処置する組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335007T1 (de) * 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
CA2505355A1 (en) * 2002-11-07 2004-05-27 Applied Neurosolutions Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
US10555915B2 (en) * 2009-08-24 2020-02-11 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
WO2018081614A1 (en) * 2016-10-31 2018-05-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis

Similar Documents

Publication Publication Date Title
JP5753152B2 (ja) アミロイドーシスを処置するための製剤および方法
JP2019537582A5 (enExample)
JP2011527339A5 (enExample)
JP7339955B2 (ja) 安定したアスコルビン酸組成物およびそれを使用する方法
JP2002537340A5 (enExample)
Basu et al. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children
JP2025060686A5 (enExample)
RU2007102698A (ru) Композиции и способы лечения неврологических нарушений
JP2015523346A5 (enExample)
JP2018514510A5 (enExample)
US20230285373A1 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JPWO2019213245A5 (enExample)
JP2007535498A5 (enExample)
CN110461329A (zh) 治疗血癌的PPARγ激动剂
JP2020527138A5 (enExample)
US20210137861A1 (en) Methods for reducing accumulated pathologic tau protein
CN1447688A (zh) 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法
US20230201151A1 (en) Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
JP2016506931A5 (enExample)
JP2021522205A (ja) 敗血症および敗血症性ショックの治療
JP2013507443A5 (enExample)
Parish et al. The treatment of acne vulgaris with low dosage doxycycline
EP3322482B1 (en) Topical ciprofloxacin compositions
JPWO2021186245A5 (enExample)
Kaji et al. A side effect of neuraminidase inhibitor in a patient with liver cirrhosis